Genmab

	8/6 09:33 af Klarussen	Short Genmab stabil 0,43%, fint, fint. Og det gode ved shorts er jo at de skal købes tilbage på et tidspunkt som Buffet siger ;-)
	8/6 07:50 af ProInvestorNEWS	Shortpositioner på danske aktier (link)
	8/6 06:39 af Stroka	God morgen :-)
	8/6 06:21 af Helge Larsen/PI-redaktør	Godmorgen :-)
	7/6 10:51 af E L	oh good question, i had assumed RR as that is usually the case for a first approval ...
	7/6 10:48 af Bulder	As far as I remember Genmab was planning to file epco for approval in FL this year. But I don’t remember if it was RR or 1L. Do you?
	7/6 10:12 af E L	easier article maybe - Positive Responses Seen in Follicular Lymphoma When Epcoritamab Is Added to Rituximab and Lenalidomide (link)
	7/6 10:04 af E L	(versus the the immediate prior therapy they progressed on, 85% and 58% respectively)
	7/6 10:02 af E L	104 efficacy evaluable patients treated with epcoritamab at 48 mg plus R2, the overall response rate (ORR) was 98% (median follow-up, 11.4 months). The complete metabolic response (CMR) was 87%
	7/6 10:01 af E L	so the first article is the new/later cutoff date of January 31, 2023; results very similar
	7/6 09:49 af E L	Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. (link)
	7/6 09:47 af E L	Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma (link) (this was the oral presentation)
	6/6 21:22 af Pensionisten	Tak for den gode artikel, @Bulder. Den var til at forstå - selv for mig! Og det siger ikke så lidt ;-)
	6/6 20:55 af Bulder	God og grundig artikel, der belyser “styrkeforholdet” epco/glofi/car-t.
	6/6 20:54 af Bulder	(link)
	6/6 20:52 af Bulder	Dansk begejstring over FDA-godkendelse af epcoritamab: Det er et stort fremskridt
	6/6 20:27 af E L	longer term results of patients with DLBCL treated with epcoritamab+R-CHOP. The latest results support the preliminary data and this treatment induces high CMR rates with a manageable safety profile (link)
	6/6 16:39 af Solsen	Lidt om Car-T (link)
	6/6 15:52 af bikube	Den 22. maj hævede han fra 47 til 51. Det svarer til lidt over 3500 i DK.
	6/6 14:51 af Klarussen	Lyder meget rimeligt
	6/6 12:37 af E L	Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (GMAB – Research Report) today and set a price target of $51.00.
	6/6 08:34 af Pensionisten	(link)
	6/6 08:33 af Pensionisten	Fireside Goldman Sachs - desværre ikke Jan, der deltager (link)
	6/6 06:54 af Solsen	(link) Osimertinib vækker opsigt. Amivantamab går efter det marked (Tagrisso) i kombi med Lazertinib.

	6/6 06:41 af bibob	Sorry. Havde ikke set E L link 21.07 ;-)
	6/6 06:28 af bibob	Fra ASCO. (link)
	5/6 21:33 af Bulder	Jamen er det ikke hvad vi altid har sagt? Og når de så lægger dara oveni, så får vi ORR-rater på 105%. :-) Jeg tør slet ikke tænke på, hvad der vi når op på, når superdara kommer.
	5/6 21:07 af E L	J&J’s multiple myeloma combo produces déjà vu with 96% Carvykti-like response (link)
	5/6 20:03 af E L	Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma (link)
	5/6 16:13 af E L	another Hemophilia trial for Daratumumab ITI Using SCT800 Combining Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor (link)
	5/6 09:59 af Bulder	Peter 23:40: ja men jeg tvivler på at Mariposa når med på asco til næste år.
	5/6 09:53 af E L	SC dosing of amivantamab significantly improved IRR safety profile (16% vs 67% for IV) (link) That should make this drug much much more tolerable
	5/6 09:13 af E L	the amivantamab posters are now all available (link)
	4/6 23:40 af peter12	Der kører også fase 3 studier (link)
	4/6 23:23 af Bulder	Ja, her begynder det at ligne noget. Desværre dog kun fase 1.
	4/6 20:58 af peter12	Wau det lyder godt ;-) Det er i 1L ?
	4/6 19:58 af E L	New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer
	4/6 19:58 af E L	(link)
	4/6 17:08 af Bulder	Thx E L
	4/6 17:08 af Bulder	Not much difference between Tal mono and Tal + dara in RR MM?
	4/6 11:36 af E L	First Results From the RedirecTT-1 Study With Teclistamab + Talquetamab Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (link)
	4/6 11:35 af E L	(link)
	4/6 11:35 af E L	Dual Bispecific Combination Teclistamab/Talquetamab Displays High Activity in RRMM (link)
	4/6 11:31 af E L	Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Updated TRIMM-2 Results (link)
	4/6 11:29 af E L	TRiMM-2: Response Rate of 78% Seen in Patients Who Receive Talquetamab With Subcutaneous Daratumumab for Multiple Myleoma (link)
	4/6 11:28 af E L	Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma (link)
	4/6 11:19 af SEACOP	Donation med stor tak for al den gode information, som tilflyder mig. (link)
	3/6 20:16 af ProInvestorNEWS	(Generel orientering).
	3/6 20:15 af ProInvestorNEWS	ASCO Daily: Analysis and insight from Friday and Saturday's key presentations (link)
	3/6 12:10 af Klarussen	Thanks E L Keep `em coming :-)